ARDS Clinical Network Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol versus Placebo for the Treatment of Acute Lung Injury (ALTA)

Objectives

This study was a prospective, randomized trial of aerosolized Albuterol vs. Placebo to test the safety and efficacy of aerosolized beta-2 adrenergic agonist therapy for improving clinical outcomes in patients with acute lung injury. Patients were followed for 90 days or until discharge from the hospital to home with unassisted breathing, whichever occurs first. The primary efficacy variable was ventilator-free days to study day 28. This study was stopped for futility after 282 patients.

Interested parties should review the Proprietary Study application process before they begin. Requests for Proprietary Studies must be approved by the Parent Study before they can be processed by BioLINCC. Contact information for the Parent Study is provided at the top of this webpage. Upon Parent Study approval, click the Request button to start a request through BioLINCC.